Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
SOPHIA: Margetuximab and chemo versus trastuzumab and chemo in HER2 positive MBC after prior anti-HER2 therapies

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.06.19
Views: 610
Rating:

Prof Hope Rugo - University of California, San Francisco, USA

Prof Hope Rugo talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the primary analysis from the phase III randomised SOPHIA trial which compares margetuximab and chemotherapy with FOLFOXIR I in HER2 positive metastatic breast cancer (MBC) after prior anti-HER2 therapies.

She explains that margetuximab is an antibody, novel to HER2, which is designed to activate the immune response, something which is of great importance to trastuzumab efficacy.

Prof Rugo reports that progression free survival was prolonged in patients randomised to receive margetuximab over trastuzumab and, although the difference was small, it was statistically significant.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation